Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Evolent Health Inc’s stock clocked out at $11.64, down -1.27% from its previous closing price of $11.79. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 4.35 million shares were traded. EVH stock price reached its highest trading level at $12.065 during the session, while it also had its lowest trading level at $11.54.
Ratios:
To gain a deeper understanding of EVH’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.98 and its Current Ratio is at 0.98. In the meantime, Its Debt-to-Equity ratio is 1.14 whereas as Long-Term Debt/Eq ratio is at 0.92.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $15.
On December 03, 2024, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $36 to $29.
Stephens Downgraded its Overweight to Equal-Weight on November 08, 2024, whereas the target price for the stock was revised from $38 to $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 06 ’25 when Holder Diane bought 2,735 shares for $9.33 per share. The transaction valued at 25,518 led to the insider holds 70,584 shares of the business.
McCarthy Daniel Joseph bought 11,040 shares of EVH for $99,470 on Mar 06 ’25. The PRESIDENT now owns 389,004 shares after completing the transaction at $9.01 per share. On Mar 07 ’25, another insider, Jelinek Richard M, who serves as the Director of the company, bought 30,000 shares for $9.12 each. As a result, the insider paid 273,750 and bolstered with 15,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVH now has a Market Capitalization of 1366536064 and an Enterprise Value of 2121386624. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.57 while its Price-to-Book (P/B) ratio in mrq is 1.44. Its current Enterprise Value per Revenue stands at 0.884 whereas that against EBITDA is 25.125.
Stock Price History:
The Beta on a monthly basis for EVH is 0.82, which has changed by -0.39089483 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, EVH has reached a high of $33.63, while it has fallen to a 52-week low of $7.06. The 50-Day Moving Average of the stock is 25.39%, while the 200-Day Moving Average is calculated to be -11.95%.
Shares Statistics:
It appears that EVH traded 2.60M shares on average per day over the past three months and 4179460 shares per day over the past ten days. A total of 115.86M shares are outstanding, with a floating share count of 114.13M. Insiders hold about 2.78% of the company’s shares, while institutions hold 108.96% stake in the company. Shares short for EVH as of 1749772800 were 15225384 with a Short Ratio of 5.86, compared to 1747267200 on 16724281. Therefore, it implies a Short% of Shares Outstanding of 15225384 and a Short% of Float of 13.13.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Evolent Health Inc (EVH) is currently shaped by the ongoing analysis conducted by 10.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.1, with high estimates of $0.18 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.59 and $0.21 for the fiscal current year, implying an average EPS of $0.38. EPS for the following year is $0.59, with 11.0 analysts recommending between $0.89 and $0.38.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $459.43M. It ranges from a high estimate of $467.87M to a low estimate of $447.2M. As of the current estimate, Evolent Health Inc’s year-ago sales were $647.14MFor the next quarter, 14 analysts are estimating revenue of $537.7M. There is a high estimate of $556.1M for the next quarter, whereas the lowest estimate is $495.24M.
A total of 14 analysts have provided revenue estimates for EVH’s current fiscal year. The highest revenue estimate was $2.08B, while the lowest revenue estimate was $2.01B, resulting in an average revenue estimate of $2.05B. In the same quarter a year ago, actual revenue was $2.55BBased on 14 analysts’ estimates, the company’s revenue will be $2.39B in the next fiscal year. The high estimate is $2.66B and the low estimate is $2.23B.
